Inhibition of LpxC Increases Antibiotic Susceptibility in Acinetobacter baumannii
Author(s) -
Meritxell GarcíaQuintanilla,
José Manuel CaroVega,
Marina R. Pulido,
Patricia Moreno-Martínez,
Jerónimo Pachón,
Michael J. McConnell
Publication year - 2016
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00407-16
Subject(s) - acinetobacter baumannii , imipenem , tigecycline , microbiology and biotechnology , amikacin , ciprofloxacin , antibiotics , vancomycin , biology , pharmacology , chemistry , bacteria , staphylococcus aureus , antibiotic resistance , pseudomonas aeruginosa , genetics
LpxC inhibitors have generally shown poorin vitro activity againstAcinetobacter baumannii . We show that the LpxC inhibitor PF-5081090 inhibits lipid A biosynthesis, as determined by silver staining and measurements of endotoxin levels, and significantly increases cell permeability. The presence of PF-5081090 at 32 mg/liter increased susceptibility to rifampin, vancomycin, azithromycin, imipenem, and amikacin but had no effect on susceptibility to ciprofloxacin and tigecycline. Potentiating existing antibiotics with LpxC inhibitors may represent an alternative treatment strategy for multidrug-resistantA. baumannii .
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom